Search

Displaying results 2861 - 2870 of 6076 in total
  1. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    [L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. … Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women

  2. Drug

    Estradiol cypionate

    go.drugbank.com/drugs/DB13954
    ApprovedVet approved

    Estradiol cypionate is commercially available as Depo-Estradiol, an intramuscular depot injection used for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the treatment

    Categories: Hormonal Contraceptives for Systemic Use
  3. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.

  4. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

  5. Drug

    Hydroxyamphetamine

    go.drugbank.com/drugs/DB09352
    Approved

    Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test.

  6. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma … [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma

  7. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

  8. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.

  9. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

  10. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also s...

    Categories: Drugs for Functional Gastrointestinal Disorders